3rd Quarter - Report

BROWN RUDNICK LLP for EXELA HOLDINGS, LLC

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Implementation of P.L. 112-144 (FDA Safety and Innovation Act) and P.L. 113 - 54 (Drug Quality and Security Act); Issues relating to ANDA approval

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
LISA LAYMAN —
HENRY W MENN —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.